Trump's FDA Nominee Heidi Overton Faces Senate Scrutiny on Vaccines and Abortion

The story so far

12 publishers have covered this in 22 articles since 22 Sept 2026. STAT published first, on 22 September at 17:49 UTC; Washington Post followed 39h 11m later. The most recent article, from Ars Technica, appeared on 25 September at 23:00 UTC.

Outlets reporting it: Washington Post (major outlet), The New York Times (major outlet), The Hill (major outlet), The Guardian US (major outlet), NPR Health (major outlet), Ars Technica (major outlet), STAT, Scientific American, Fox News Politics, Mother Jones, Roll Call, MedPageToday.com - medical news for physicians.

3 prediction markets price this story:

• Before Dec 1, 2026 — the market puts it at 16%, closing 1 Dec 2026. The outcome is Yes if Heidi Overton becomes the first confirmed Commissioner of the FDA before December 1, 2026. The outcome is No if she does not hold that specific title within the deadline. Readers often mistake any confirmation hearing for an actual confirmation.
• Mitch McConnell — the market puts it at 37%, closing 1 Jan 2028. The market resolves to Yes if Mitch McConnell votes in favor of FDA nominee Heidi Overton before January 1, 2028. Otherwise, it resolves to No. Readers often mistake the date of the confirmation hearing for the deadline, but only the actual vote counts.
• Skin cancer vaccine FDA approved by September 30, 2027? — the market puts it at 42%, closing 1 Jan 2028. The market resolves to Yes if the FDA issues an approval letter for intismeran autogene by September 30, 2027, at 11:59 PM ET. It resolves to No if that specific deadline passes without such an approval. Readers often mistake a positive clinical trial result or an Approvable Letter for a final approval.

Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.